Comments on Negotiation Data Elements and Evidence about Alternative Treatments for the Medicare Drug Price Negotiation Program

Written By Danielle Bargo
Danielle Bargo
Previous

CMS should aspire to an analytically rigorous approach to drug price negotiations
Next

Prescription Drug Pricing Reform: The Bark Is Bigger Than The Bite